You must be 21 years or older to access this website. All products are for research use only.
Are you 21 years of age or older?
By entering, you confirm that you are at least 21 years old and agree to our terms of service.
CJC-1295 / Ipamorelin · Published March 8, 2026 · Updated May 18, 2026 · 7 min read
CJC-1295 No DAC plus Ipamorelin is a research blend pairing a short-acting GHRH analog with a selective ghrelin receptor agonist to study pulsatile growth hormone release. Researchers examine combined receptor activation, pulse kinetics, and IGF-1 dynamics across rodent models. For research use only, not for human consumption.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
CJC-1295 (No DAC) combined with Ipamorelin has become a widely studied peptide blend in laboratory environments focused on growth hormone-related signaling pathways. Used strictly for research purposes, this combination allows investigators to examine how distinct peptide mechanisms interact when introduced together under controlled experimental conditions.
CJC-1295 is a synthetic 30-amino-acid analog of growth hormone-releasing hormone (GHRH). It is studied in research models as a long-acting GHRH receptor agonist that drives pulsatile growth hormone release from the pituitary.
The no-DAC form provides a sharp, time-limited GHRH signal that aligns with the rapid ghrelin receptor signaling from Ipamorelin, producing discrete synergistic GH pulses that more closely mimic physiological pulse architecture than sustained DAC-mediated GHRH exposure.
Rodent and clinical research protocols typically use subcutaneous administration two to three times daily, often timed to align with endogenous GH pulse windows including pre-sleep dosing for nocturnal pulse amplification studies.
No. CJC-1295 is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.
Key terms used in this article.
Continue exploring research insights and updates.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
CJC-1295 (No DAC) and Ipamorelin operate through different but complementary biological pathways. CJC-1295 (No DAC) is a growth hormone-releasing hormone (GHRH) analog, while Ipamorelin is classified as a growth hormone secretagogue receptor (GHS-R) agonist. When studied together, researchers can observe how simultaneous pathway activation influences signaling patterns in vitro.
CJC-1295 (No DAC) differs from its DAC-containing counterpart by excluding the drug affinity complex, resulting in a shorter half-life. This structural difference makes it especially useful for researchers who require tighter control over exposure windows during experimentation. Its activity allows investigators to analyze pulsatile signaling behavior without prolonged systemic presence.
Ipamorelin is recognized in research literature for its selective binding to the growth hormone secretagogue receptor. Unlike earlier compounds in this category, Ipamorelin demonstrates a narrower receptor interaction profile, making it valuable for studies aiming to isolate specific signaling responses without broad receptor activation.
The absence of DAC in CJC-1295 allows researchers to observe more immediate and transient signaling effects. This makes the No DAC version particularly useful for time-sensitive assays, repeated-measure protocols, and comparative studies evaluating short-duration versus extended-release peptide activity.
For research integrity, proper handling and storage are essential. CJC-1295 (No DAC) and Ipamorelin are typically supplied as lyophilized powders to maintain stability during transport and storage. Researchers should follow established laboratory protocols to ensure sample consistency and reliability throughout experimentation.
Studying peptides in combination allows researchers to observe interaction effects that may not be evident when compounds are evaluated individually. The CJC-1295 (No DAC) and Ipamorelin blend provides a structured framework for analyzing how distinct signaling routes behave concurrently under controlled laboratory conditions.
Published research has examined dual-pathway activation mechanisms, with findings suggesting that combination approaches yield more comprehensive understanding of receptor behavior and signaling coordination in laboratory models.
At Midwest Peptide, our CJC-1295 (No DAC) and Ipamorelin blend is supplied with comprehensive quality documentation:
Understanding the characteristics of CJC-1295 (No DAC) and Ipamorelin allows researchers to design more informed and controlled experiments. By selecting well-documented research compounds, laboratories can maintain consistency, accuracy, and clarity across their peptide studies.
Designed for research professionals seeking reliable peptide compounds, this blend supports structured investigation into growth hormone-related signaling pathways within compliant laboratory environments.
Independent research has examined both halves of this blend in considerable detail, and the published record is what makes the combination interesting to investigators rather than the marketing around it.
For CJC-1295, the most cited primary work is the Teichman et al. analysis in the Journal of Clinical Endocrinology & Metabolism series indexed at ScienceDirect, which characterized serum protein profile changes following CJC-1295 administration. The DAC-bound variant produced sustained elevations of growth hormone and IGF-1 for 6 to 14 days, with no tachyphylaxis at the doses tested. The No DAC variant studied here has a much shorter half-life, on the order of 30 minutes, which is the precise feature that makes it useful for time-resolved signaling work. Investigators who want to map a single GH pulse rather than a multi-day plateau intentionally choose the No DAC version because it allows the somatotroph response to return to baseline before the next experimental challenge.
For Ipamorelin, the foundational receptor characterization is summarized in Howard et al.'s ScienceDirect-indexed work on growth hormone secretagogues, which placed ipamorelin in the GHS-R1a agonist class alongside hexarelin and GHRP-6 but noted its much narrower endocrine fingerprint. Where GHRP-6 elevates cortisol and prolactin alongside GH, ipamorelin's pentapeptide structure (Aib-His-D-2-Nal-D-Phe-Lys-NH2) produces a GH pulse without measurable changes in adrenocorticotropic hormone, cortisol, or prolactin in the model systems studied. That selectivity is the entire reason ipamorelin replaced earlier GHRPs in many research programs.
The blend's research interest comes from convergent signaling at the somatotroph. GHRH analogs act through a Gs-coupled receptor that elevates cyclic AMP and increases GH transcription, while ghrelin receptor agonists act through a Gq/11-coupled pathway that mobilizes intracellular calcium. The two cascades meet at vesicle exocytosis. When both pathways fire together, the magnitude of the GH pulse exceeds the simple sum of either input alone, an effect that has been replicated across multiple in vitro pituitary cell preparations. For an overview of how pulsatile GH signaling differs from sustained exposure at the tissue level, Nature Reviews Endocrinology's analysis of ghrelin and GH pulse architecture is the current reference text.
Researchers comparing the blend to single-peptide controls typically build a four-arm protocol: vehicle, CJC-1295 No DAC alone, Ipamorelin alone, and the combined administration. Sampling intervals are kept short, usually every 10 to 15 minutes for the first 90 minutes post-administration, to capture the leading and trailing edges of the GH pulse. Without that temporal resolution the synergistic peak is easy to miss. Investigators interested in downstream effects extend collection windows for IGF-1, IGFBP-3, and selected lipolysis markers to the 24 to 72 hour range, because those analytes integrate over multiple GH pulses rather than tracking a single secretory event. The CJC/Ipamorelin blend product page lists the standard 5 mg of each component per vial used in most published protocols.
Primary literature and topic hubs from peer-reviewed publishers covering this area of research:
Explore more peer-reviewed research and laboratory guides from our science team:
All products are third-party tested with a Certificate of Analysis (COA) included. For research use only.
Browse our full catalog of research-grade peptides. Every product is third-party tested with a COA included.
Browse ProductsMidwest Peptide supplies research-grade CJC-1295 with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.
The cheapest tirzepatide (GLP-2 TZ) for research is rarely the best value. Here is how to balance price against the analytical specifications that determine research utility.
May 5, 2026
